PPAR delta

01/25/2010 - "In conclusion, PPARdelta agonism alleviates insulin resistance and improves islet function and topography, resulting in improved glycemia in diabetic db/db mice. "
04/01/2010 - "Our results point to PPARdelta activation as a pharmacological target to prevent insulin resistance."
06/01/2009 - "PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair."
06/01/2008 - "However, adoptive transfer of PPARdelta(-/-) (Ppard(-/-)) bone marrow into wild-type mice diminishes alternative activation of hepatic macrophages, causing hepatic dysfunction and systemic insulin resistance. "
06/01/2008 - "The physiological relevance of this paracrine pathway is demonstrated in myeloid-specific PPARdelta(-/-) mice, which develop insulin resistance and show increased adipocyte lipolysis and severe hepatosteatosis. "

12/01/2003 - "They strongly support the idea that activation of PPARdelta could be beneficial in prevention of metabolic disorders, such as obesity or type 2 diabetes."
01/01/2012 - "Neuron-specific deletion of peroxisome proliferator-activated receptor delta (PPARδ) in mice leads to increased susceptibility to diet-induced obesity."
01/29/2010 - "We thus hypothesized that obesity observed in ovariectomized mice, a model of menopause, may result in part from abrogated expression of muscle PPARdelta and/or downstream mediators such as FoxO1. "
01/01/2010 - "In vivo, obesity has led to downregulation of adipose PPARdelta expression. "
01/01/2008 - "PPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities."

07/01/2010 - "This study demonstrated that PPARdelta agonist and EGCG decreased the AGE-induced kidney cell inflammation and apoptosis. "
01/01/2015 - "Therefore, FXR can exert its hepatoprotective functions by controlling inflammation and mitochondrial functions, possibly involving an FXR-PPAR delta cross-talk."
08/02/2010 - "Collectively, these findings suggest that PPAR-delta serves as an important molecular brake for the control of autoimmune inflammation."
05/01/2008 - "The results indicate that activation of PPAR-delta protected the heart from I/R injury in Zucker fatty rats, and multiple mechanisms including amelioration of lipotoxicity, anti-inflammation, and up-regulation of prosurvival signaling contribute together to the cardioprotection."
03/01/2006 - "PPARdelta enhances fatty acid catabolism and energy uncoupling in adipose tissue and muscle, and it suppresses macrophage-derived inflammation. "

07/01/2008 - "[Roles of PPAR-delta in atherosclerosis]."
03/18/2008 - "PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis."
02/01/2008 - "PPAR-delta agonists may have a potential for treating inflammatory diseases such as atherosclerosis and diabetes."
01/01/2008 - "Therefore, it is suggested that PPAR-delta may have critical roles in cardiovascular pathophysiology and is a potential target for therapeutic intervention of cardiovascular disorders such as atherosclerosis."
07/01/2007 - "Recent literature has suggested the benefit of selective PPARdelta agonists for the treatment of atherosclerosis and other disease states associated with the metabolic syndrome. "

04/05/2007 - "These data suggest that selective PPARdelta agonists have the potential to become a novel treatment of dyslipidemia."
06/01/2005 - "It is indicated that PPARdelta + 294T/C gene polymorphism in subjects with MS may be involved in the occurrence of obesity and dyslipidemia. "
04/01/2010 - "Previous studies have identified a single-nucleotide polymorphism in the gene encoding peroxisome proliferator-activated receptor-delta (PPARD), rs2016520, that is associated with changes in metabolic disease in some but not all studies, which suggests that PPARD agonists may have therapeutic benefits for the treatment of metabolic disorders, including dyslipidemia, type 2 diabetes, and obesity. "
05/01/2008 - "We tested whether pharmacological activation of PPAR-delta protects the heart from ischemia/reperfusion (I/R) injury in male Zucker fatty rats, a rodent model of obesity and dyslipidemia. "
12/01/2004 - "Based on this work it looks as if PPARdelta agonists currently in development for treatment of dyslipidemias and obesity may increase the risk of tumor formation in humans. "